Streetbeat News

Stock Prices

LQDA

UTHR

The Federal Circuit has affirmed an earlier PTAB decision to invalidate all claims of United Therapeutics' patent No. 10,716,793. Liquidia will seek to lift the injunction imposed by the District Court in Delaware and continue pursuing FDA approval for YUTREPIA.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 9:58 pm

PARA

WBD

CEOs of Warner Bros. Discovery, Inc. (WBD) and Paramount Global discussed a potential merger, focusing on mutual benefits such as leveraging children's programming and combining news outlets. The merger could create a media giant and is driven by Paramount's debt and competition from Big Tech. Warner Bros. Discovery has hired bankers to explore the deal, and CEO David Zaslav has spoken with Shari Redstone, owner of Paramount's parent company. Both companies' stocks were down in after-hours trading.

Portfolio Pulse from Ryan Gustafson

December 20, 2023 | 9:53 pm

IPHA

Innate Pharma has filed an F-3 form with the SEC, indicating its intention to offer and sell up to $200 million worth of stock in shelf offerings. This move allows the company to sell shares over time, providing flexibility in financing its operations or growth initiatives.

Portfolio Pulse from Charles Gross

December 20, 2023 | 9:51 pm

BKX

KEY

KeyCorp (NYSE:KEY) received an analyst upgrade from Terry McEvoy of Stephens from Equal Weight to Overweight, maintaining a price target of $16.50. The upgrade is based on KeyCorp's strong balance sheet and anticipated net interest income growth, which is expected to outperform peers from 2023 to 2025. Despite the sector's pressure from bank failures earlier this year, KeyCorp's position is seen as superior. Shares of KeyCorp were down 1.9% to $14.08 on Wednesday.

Portfolio Pulse from Priya Nigam

December 20, 2023 | 9:49 pm

CALT

Calliditas Therapeutics' stock is trading higher following the announcement of the full FDA approval of their drug TARPEYO.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 9:45 pm

FEAM

5E Advanced Materials has filed an S-1 form with the SEC, indicating its intention to offer up to $50 million in stock through a shelf registration. This move allows the company to sell shares in one or more offerings at a future date.

Portfolio Pulse from Charles Gross

December 20, 2023 | 9:44 pm

ATRA

Atara Biotherapeutics' stock is trading higher following the announcement of the completion of an expanded global partnership with Pierre Fabre Laboratories for the development and commercialization of tabelecleucel.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 9:40 pm

CALT

The FDA has approved Calliditas Therapeutics' TARPEYO delayed release capsules for adults with primary IgAN at risk of disease progression. TARPEYO, also known as NEFECON, showed a statistically significant benefit over placebo in reducing the loss of kidney function over a two-year study period. The treatment resulted in 50% less deterioration of kidney function compared to placebo and is the only FDA-approved treatment for IgAN that targets the production of pathogenic antibodies causing the disease.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 9:35 pm

AYRO

CAAS

CJET

DBGI

ELA

FORD

LTRY

LXEH

NOGN

SECO

TBLT

In Wednesday's after-market session, several consumer discretionary stocks experienced significant movements. Gainers included Secoo Holding, Forward Industries, Visionary Education Tech, Envela, ToughBuilt Industries, and China Automotive Systems, with increases ranging from 5.15% to 11.4%. Conversely, Lixiang Education Hldg, AYRO, Digital Brands Group, Chijet Motor Co, Nogin, and Lottery.com saw their stock prices decline between 3.23% and 6.5%.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 9:31 pm

ATRA

AVTX

MLTX

TCBP

ZJYL

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Atara Biotherapeutics (ATRA) saw a 24.3% increase, while MoonLake (MLTX) rose by 12.98%. TC BioPharm (TCBP), Perspective Therapeutics (CATX), Lucy Scientific Discovery (LSDI), and Calliditas Therapeutics (CALT) also posted gains. Conversely, Jin Medical International (ZJYL) led the losers with a 10.7% decline, followed by Avalo Therapeutics (AVTX), Eiger BioPharmaceuticals (EIGR), Monogram Orthopaedics (MGRM), LogicMark (LGMK), and Aclarion (ACON) with notable decreases.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 9:31 pm